Promising New Data on Self-delivering RNAi Compounds
News May 13, 2015
New data from one of the company's discovery stage programs was presented at the latest meeting of the Society of Investigative Dermatology. Their research showed that sd rxRNA compounds developed to target TYR, lead to a visible reduction in pigmentation in cultured melanocytes. In vitro experiments have been carried out using a 3 dimensional tissue culture model of human epidermis that contains melanocytes. The results of these experiments show that sd-rxRNA compounds targeting tyrosinase, in this model, are at least one hundred times more potent than kojic acid, a well-characterized skin lightening agent in reducing the melanin production in melanocytes.
They also presented results on sd-rxRNA compounds targeting MMP1. In this discovery program, multiple potent sd-rxRNAs that target MMP1 have been identified and evaluated. The data displayed show a reduction in MMP1 mRNA levels that corresponds to a similar reduction in MMP1 enzyme activity in HT-1080 cells, a cell line useful for research related to cancer of connective tissues. In addition, silencing of MMP1 expression in an in vitro scratch assay resulted in reduced migration of A549 cells, a clinically relevant non-small cell lung cancer cell line. Reduced migration in a scratch assay may indicate a reduction in the invasive nature of the cancer cell due to MMP1 reduction as a result of sd-rxRNA treatment.
"We are excited to move these discovery programs forward," said Dr. Karen Bulock, Vice President of Research at RXi Pharmaceuticals. She further added, "Not only do these TYR inhibitors have the potential to treat pigmentation disorders, both the TYR and MMP1 compounds may also be useful as adjuvant therapy for diseases such as melanoma and possibly cancer metastasis, respectively."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018